Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2005
03/23/2005CN1599616A Storage-stable human fibrinogen solutions
03/23/2005CN1599605A Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
03/23/2005CN1599603A Method of stabilizing reduced coenzyme Q10
03/23/2005CN1599601A Plaster for the treatment of dysfunctions and disorders of nails
03/23/2005CN1599600A Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
03/23/2005CN1599599A Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine
03/23/2005CN1599598A Controlled release polymeric compositions of bone growth promoting compounds
03/23/2005CN1599594A Solid oral compositions
03/23/2005CN1599577A Peptide-based multimeric targeted contrast agents
03/23/2005CN1596984A Malt injection and its processing technology
03/23/2005CN1596983A Composition of nanometer SOD and ginseng or its extract and its preparation method
03/23/2005CN1596982A Composition of nanometer SOD and astragalus root or its extract and its preparation method
03/23/2005CN1596981A Composition of nanometer SOD and pueraria root or its extract and its preparation method
03/23/2005CN1596891A Preparation method of captopril compounding chitin polysaccharide slow release micro ball
03/23/2005CN1596878A Oral medicine possessing colon orientation medicine releasing function
03/23/2005CN1194024C Cosmetic and /or pharmaceutical preparations with polymers containing polysiloxanes and the uses thereof
03/23/2005CN1194014C Coupled cmpound of hematopoietin and polyethylene glycol
03/23/2005CN1193792C Stable medicinal composition for oral use
03/23/2005CN1193791C Ordered molecualr presentation of antigens. method of preparation and use
03/23/2005CN1193788C Beta 2-adrenergic receptor agonist
03/23/2005CN1193759C Sustained release and implantation type cis-platinum medicine and method for preparing same
03/23/2005CN1193757C Sustained release ranolazine formulations
03/23/2005CN1193752C Tetrahydrolipstatin-containing compositions
03/23/2005CN1193743C Multilayer pharmaceutical product for release in the colon
03/23/2005CN1193740C Fast dispersing dosage forms free of mamal gelatin
03/22/2005US6870033 Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
03/22/2005US6870029 Method of diagnosing and treating gliomas
03/22/2005US6869976 Dispersion or complexes of calcium sulfate in polymers such as polyethylene glycol or dextran sulfate; is a solid matrix due to hydration; especially containing an antibiotic for treating bone disorders
03/22/2005US6869973 Nitrosated and nitrosylated taxanes, compositions and methods of use
03/22/2005US6869942 Comprises formoterol and corticosteroid; for use in treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease
03/22/2005US6869939 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
03/22/2005US6869938 Gels for use as bioadhesives
03/22/2005US6869932 Immobilizated growth hormone releasing factor
03/22/2005US6869789 Heparinase III and uses thereof
03/22/2005US6869624 Product and process for stabilizing Aloe vera gel
03/22/2005US6869615 Enterically coated to prevent gastrointestinal side effects
03/22/2005US6869607 Vaccine formulations
03/22/2005US6869606 Can be reversibly dissociated in the presence of free biotin, allowing adjustment of concentration by exposing the complex to varying amounts of free biotin
03/22/2005US6869604 Ribonuclease with anti-tumor activity that retains its activity when produced as a single chain fusion protein
03/22/2005US6869590 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
03/22/2005US6869588 Stimulus sensitive gel with radioisotope and methods of making
03/22/2005CA2379672C Biodegradable poly(alkylene oxide)-poly(p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same
03/22/2005CA2209673C Solid medicament form with active agent distributed in polymer material
03/19/2005CA2441653A1 Targeted ligands
03/17/2005WO2005024038A2 Process for producing a capsular polysaccharide for use in conjugate vaccines
03/17/2005WO2005023844A1 Compound modified with glycerol derivative
03/17/2005WO2005023834A2 Peptides and compounds that bind to thrombopoietin receptors
03/17/2005WO2005023310A2 Polyamine-metal chelator conjugates
03/17/2005WO2005023309A2 Design of re-targeted toxin conjugates
03/17/2005WO2005023308A1 Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
03/17/2005WO2005023294A2 Polyacetal drug conjugates as release system
03/17/2005WO2005023282A1 Nanoparticle containing physiologically active protein or peptide, process for producing the same and external preparation comprising the nanoparticle
03/17/2005WO2005023259A1 Itraconazole solution
03/17/2005WO2005023249A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
03/17/2005WO2005023233A2 Antimicrobial compositions and methods
03/17/2005WO2005023222A1 Pharmaceutical composition with improved solubility and fluidity
03/17/2005WO2005023217A2 Granular sustained release preparation and production thereof
03/17/2005WO2005023181A2 Polymeric systems for controlled drug therapy
03/17/2005WO2005023177A2 Human monoclonal antibodies against bacillusanthracis protective antigen
03/17/2005WO2005023176A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides
03/17/2005WO2005023175A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
03/17/2005WO2005023096A2 Methods and compositions for ultrasound imaging of apoptosis
03/17/2005WO2005011635A3 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
03/17/2005WO2005004838A8 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof
03/17/2005WO2005002643A3 Method and products for delivering biological molecules to cells using multicomponent nanostructures
03/17/2005WO2004108116A3 Stabilized particle dispersions containing surface-modified inorganic nanoparticles
03/17/2005WO2004103408A3 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
03/17/2005WO2004096266A8 Improved physical stability of insulin formulations
03/17/2005WO2004087213A8 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
03/17/2005WO2004082708A3 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
03/17/2005WO2004074434A3 Methods and compositions for administering therapeutic and diagnostic agents
03/17/2005WO2004049358A3 Multifunctional particulate material, fluid, and composition
03/17/2005WO2004047871A3 Modified naturetic compounds, conjugates, and uses thereof
03/17/2005WO2004043486A8 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
03/17/2005WO2004032843A3 Mucoadhesive tetracycline formulations
03/17/2005WO2003101484A9 Compositions and methods for transepithelial molecular transport
03/17/2005WO2003101425A3 Therapeutic agent-containing polymeric nanoarticles
03/17/2005WO2002100343A3 N-terminally truncated galectin-3 and antibodies for treating cancer
03/17/2005WO1999034833A9 Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
03/17/2005US20050060761 Using tetanus toxin/reporter protein fusion as diagnstic tool in detection, monitoring and diagnosis of neurodegenerative disease
03/17/2005US20050059744 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
03/17/2005US20050059740 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
03/17/2005US20050059733 and stilbene oxides; 3,5-dihydroxy-4-isopropylstilbene for example; treating various immune, inflammatory, and autoimmune diseases
03/17/2005US20050059707 Benzoyl-, indanoyl- or tetrahydronaphthoyl-oxy (or thio) nicotinic acid derivatives; a kit comprising two chambers for mixing the compound in solid form with a topical carrier within seven days prior to topical administration
03/17/2005US20050059674 reducing granulation tissue in humans having otitis and an open tympanic membrane comprising topically applying an aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone
03/17/2005US20050059667 pH-dependent binder controls rate of dissolution of tablet; cardiovascular disease
03/17/2005US20050059644 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid
03/17/2005US20050059625 Immunostimulatory nucleic acid molecules
03/17/2005US20050059595 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
03/17/2005US20050059585 Methionine aminopeptidase-2 inhibitors and methods of use thereof
03/17/2005US20050059576 Targeted delivery of antiviral compounds through hemoglobin bioconjugates
03/17/2005US20050059574 Compositions of stable T3 and methodes of use thereof
03/17/2005US20050059129 Solid support comprising biopolymer matrix for use in enhancing stability of therapeutic proteins
03/17/2005US20050059122 Targeted carrier fusions for delivery of chemotherapeutic agents
03/17/2005US20050059101 Modified bifunctional protein comprising two binding moieties specific to cancer associated antigens for use as tool in tissue targeted therapy of cell proliferative diseases
03/17/2005US20050059099 PSCA: prostate stem cell antigen and uses thereof
03/17/2005US20050059087 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
03/17/2005US20050059008 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
03/17/2005US20050058767 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
03/17/2005US20050058731 Treatment for cuticles or skin tissue; may also comprise avocado oil, primrose oil, juniper oil, grapefruit oil, chamomile oil, lavender oil with an effective amount of triclosan antifungal/antimicrobial agent
1 ... 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 ... 1712